{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:17:26Z","timestamp":1780582646806,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,16]]},"DOI":"10.7759\/cureus.36212","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T07:18:03Z","timestamp":1678951083000},"source":"Crossref","is-referenced-by-count":2,"title":["COVID-19-Associated Pulmonary Aspergillosis Complicated by Severe Coronavirus Disease: Is Detection of Aspergillus in Airway Specimens Before Disease Onset an Indicator of Antifungal Prophylaxis?"],"prefix":"10.7759","author":[{"given":"Takaaki","family":"Kitayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Tone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Makimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02554-2020","article-title":"Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis","volume":"56","author":"Armstrong-James D","year":"2020","unstructured":"Armstrong-James D, Youngs J, Bicanic T, et al.. Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis. Eur Respir J. 2020, 56:2002554. 10.1183\/13993003.02554-2020","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby P","year":"2021","unstructured":"Horby P, Lim WS, Emberson JR, et al.. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021, 384:693-704. 10.1056\/NEJMoa2021436","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102568","article-title":"Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy","volume":"19","author":"Toniati P","year":"2020","unstructured":"Toniati P, Piva S, Cattalini M, et al.. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020, 19:102568. 10.1016\/j.autrev.2020.102568","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206291","article-title":"The clinical spectrum of pulmonary aspergillosis","volume":"70","author":"Kosmidis C","year":"2015","unstructured":"Kosmidis C, Denning DW. The clinical spectrum of pulmonary aspergillosis. Thorax. 2015, 70:270-7. 10.1136\/thoraxjnl-2014-206291","journal-title":"Thorax"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/myc.13096","article-title":"COVID-19 associated pulmonary aspergillosis","volume":"63","author":"Koehler P","year":"2020","unstructured":"Koehler P, Cornely OA, B\u00f6ttiger BW, et al.. COVID-19 associated pulmonary aspergillosis. Mycoses. 2020, 63:528-34. 10.1111\/myc.13096","journal-title":"Mycoses"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"Koehler P","year":"2021","unstructured":"Koehler P, Bassetti M, Chakrabarti A, et al.. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021, 21:e149-62. 10.1016\/S1473-3099(20)30847-1","journal-title":"Lancet Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1128\/aem.61.4.1323-1330.1995","article-title":"Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes","volume":"61","author":"Glass NL","year":"1995","unstructured":"Glass NL, Donaldson GC. Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes. Appl Environ Microbiol. 1995, 61:1323-30. 10.1128\/aem.61.4.1323-1330.1995","journal-title":"Appl Environ Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00551-09","article-title":"Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism","volume":"47","author":"Staab JF","year":"2009","unstructured":"Staab JF, Balajee SA, Marr KA. Aspergillus section Fumigati typing by PCR-restriction fragment polymorphism. J Clin Microbiol. 2009, 47:2079-83. 10.1128\/JCM.00551-09","journal-title":"J Clin Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00064-07","article-title":"Multilocus sequence typing of the pathogenic fungus Aspergillus fumigatus","volume":"45","author":"Bain JM","year":"2007","unstructured":"Bain JM, Tavanti A, Davidson AD, Jacobsen MD, Shaw D, Gow NA, Odds FC. Multilocus sequence typing of the pathogenic fungus Aspergillus fumigatus. J Clin Microbiol. 2007, 45:1469-77. 10.1128\/JCM.00064-07","journal-title":"J Clin Microbiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00090-2","article-title":"Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study","volume":"2","author":"Russell CD","year":"2021","unstructured":"Russell CD, Fairfield CJ, Drake TM, et al.. Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe. 2021, 2:e354-65. 10.1016\/S2666-5247(21)00090-2","journal-title":"Lancet Microbe"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200401-093OC","article-title":"Invasive aspergillosis in critically ill patients without malignancy","volume":"170","author":"Meersseman W","year":"2004","unstructured":"Meersseman W, Vandecasteele SJ, Wilmer A, Verbeken E, Peetermans WE, Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med. 2004, 170:621-5. 10.1164\/rccm.200401-093OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e31819e67b1","article-title":"Invasive pulmonary aspergillosis in patients with antineutrophil cytoplasmic antibody associated vasculitis","volume":"15","author":"Su T","year":"2009","unstructured":"Su T, Li HC, Chen M, et al.. Invasive pulmonary aspergillosis in patients with antineutrophil cytoplasmic antibody associated vasculitis. J Clin Rheumatol. 2009, 15:380-2. 10.1097\/RHU.0b013e31819e67b1","journal-title":"J Clin Rheumatol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(18)30274-1","article-title":"Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study","volume":"6","author":"Schauwvlieghe A","year":"2018","unstructured":"Schauwvlieghe A, Rijnders BJA, Philips N, et al.. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med. 2018, 6:782-792. 10.1016\/s2213-2600(18)30274-1","journal-title":"Lancet Respir Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1065","article-title":"Epidemiology of invasive pulmonary Aspergillosis among intubated patients with COVID-19: a prospective study","volume":"73","author":"Bartoletti M","year":"2021","unstructured":"Bartoletti M, Pascale R, Cricca M, et al.. Epidemiology of invasive pulmonary Aspergillosis among intubated patients with COVID-19: a prospective study. Clin Infect Dis. 2021, 73:e3606-14. 10.1093\/cid\/ciaa1065","journal-title":"Clin Infect Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202009-3400OC","article-title":"Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU","volume":"203","author":"Fekkar A","year":"2021","unstructured":"Fekkar A, Lampros A, Mayaux J, et al.. Occurrence of invasive pulmonary fungal infections in patients with severe COVID-19 admitted to the ICU. Am J Respir Crit Care Med. 2021, 203:307-17. 10.1164\/rccm.202009-3400OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"RECOVERY Collaborative Group","year":"2021","unstructured":"RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021, 397:1637-45. 10.1016\/S0140-6736(21)00676-0","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2021.08.014","article-title":"Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology","volume":"28","author":"Prattes J","year":"2022","unstructured":"Prattes J, Wauters J, Giacobbe DR, et al.. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology. Clin Microbiol Infect. 2022, 28:580-7. 10.1016\/j.cmi.2021.08.014","journal-title":"Clin Microbiol Infect"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2021.04.012","article-title":"Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review","volume":"113","author":"Chong WH","year":"2021","unstructured":"Chong WH, Neu KP. Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review. J Hosp Infect. 2021, 113:115-29. 10.1016\/j.jhin.2021.04.012","journal-title":"J Hosp Infect"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely OA","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, et al.. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007, 44:1289-97. 10.1086\/514341","journal-title":"Clin Infect Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-021-03753-9","article-title":"Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study","volume":"25","author":"Hatzl S","year":"2021","unstructured":"Hatzl S, Reisinger AC, Posch F, et al.. Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Crit Care. 2021, 25:335. 10.1186\/s13054-021-03753-9","journal-title":"Crit Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/140404-covid-19-associated-pulmonary-aspergillosis-complicated-by-severe-coronavirus-disease-is-detection-of-aspergillus-in-airway-specimens-before-disease-onset-an-indicator-of-antifungal-prophylaxis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:56:03Z","timestamp":1707508563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/140404-covid-19-associated-pulmonary-aspergillosis-complicated-by-severe-coronavirus-disease-is-detection-of-aspergillus-in-airway-specimens-before-disease-onset-an-indicator-of-antifungal-prophylaxis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.36212","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}